Human disease

Lewy body dementia

Mondo defines it as: “A progressive form of dementia characterized by the presence of protein deposits called Lewy bodies in the midbrain and cerebral cortex, and loss of cholinergic and dopaminergic neurons. The signs and symptoms overlap with Alzheimer and Parkinson disease.”

1 disease group in OMIA reaches this disease, through OMIA's own Mondo link or its OMIM numbers. The page shows the chain. It does not say whether an animal is a model of this disease.

Animal diseases

By natural-model score for this disease, highest first. The score says how complete and how well supported each chain is, by stated rules. How the score works.

OMIA group	Name	Found by	Species	The chain reached	Score
2378	Parkinson disease, SNCA-related	OMIA's OMIM numbers	4	Drug	56.0

Human genes

Each human gene of these disease groups that Open Targets links to this disease.

Human gene	Score	Evidence
SNCA	0.74	2,696

Drugs tested for this disease

Each ChEMBL drug that has been tested for this disease, and the human genes above it acts on, if any. Open Targets gives some drugs, such as most enzyme replacement therapies, no target gene.

Drug	Acts on	Latest stage for this disease
Ioflupane	None of these genes	Approved
Donepezil	None of these genes	Phase 3
Galantamine	None of these genes	Phase 3
Bosutinib	None of these genes	Phase 2
Clenbuterol	None of these genes	Phase 2
Irsenontrine	None of these genes	Phase 2
Nadolol	None of these genes	Phase 2
Neflamapimod	None of these genes	Phase 2
Nelotanserin	None of these genes	Phase 2
Nevadistinel	None of these genes	Phase 2
Nilotinib	None of these genes	Phase 2
Terazosin	None of these genes	Phase 2
Ambroxol	None of these genes	Phase 1/2
Armodafinil	None of these genes	Unknown
Fosgonimeton	None of these genes	Unknown
Ramelteon	None of these genes	Unknown
Rivastigmine	None of these genes	Unknown

The drug data is ChEMBL's, under CC BY-SA 3.0, and came through Open Targets release 26.09.